F2 and Venous thrombosis: This syndrome should be suspected in the presence of increased coagulation times (prothrombin time and activated partial thromboplastin time) in association with the presence of LA. The dual risk between bleeding and thrombosis poses significant diagnostic and therapeutic challenges, particularly in deciding whether to use anticoagulation therapy, which could exacerbate bleeding, or withhold it, which could increase the risk of thrombosis. The authors report a case of a woman with LAHPS treated with rituximab.